A study to understand more about neuroendocrine tumours
Cancer type:
Status:
Phase:
This study looked at 
in people with neuroendocrine tumours (NETs). The research team wanted to gather information that would help improve treatment in the future.
The study was supported by Cancer Research UK. It was open for people to join between 2009 and 2018. The team have published articles in several medical journals. There are links to more information in the ‘Summary of results’ section below.
More about this trial
are rare tumours that develop in nerve cells and glands of the neuroendocrine system. The neuroendocrine system makes , which control how our bodies work.
NETs can be non cancerous (benign) or cancerous (malignant).
Doctors want to understand more about neuroendocrine tumour cells, and how they grow. But it is difficult to gather information because NETs are rare.
Researchers in this study collected samples of blood, urine and cells from people with a NET. They looked at genes and genetic changes. This includes possible gene faults that run in families.
The main aim was to find genetic changes and that could help in future with diagnosing and treating NETs.
The research team looked at the samples they collected from people who took part in this study. They also worked with other research teams to find out more about people with NETs. And this led to similar research looking at people with lung cancer.
Summary of results
We aim to add a lay summary of results to all the studies on our database. Unfortunately we have not been able to include a summary for this one.
There is more information about the results in the link below.
Please note, the information we link to here is not in plain English. It has been written for healthcare professionals and researchers.
Somatic mutation of CDKN1B in small intestine neuroendocrine tumors
J Francis and others
Nature Genetics, 2013. Volume 45, issue 12, pages 1483–1486.
Correlation of Smoking-Associated DNA Methylation Changes in Buccal Cells With DNA Methylation Changes in Epithelial Cancer
A Teschendorff and others
JAMA Oncology, 2015. Volume 1, issue 4, pages 476-485.
Epigenetic dysregulation and poorer prognosis in DAXX-deficient pancreatic neuroendocrine tumours
C Pipinikas and others
Endocrine Related Cancer, 2015. Volume 22, issue 3, L13–L18.
Prognostic Impact of Novel Molecular Subtypes of Small Intestinal Neuroendocrine Tumor
A Karpathakis and others
Clinical Cancer Research, 2016. Volume 22, issue 1, pages 250-258.
Genetic clues can be used to predict whether early-stage cancer will form an invasive tumour
H Greulich and others
Nature, 2019. Issue 566, pages 336-337.
Deciphering the genomic, epigenomic, and transcriptomic landscapes of pre-invasive lung cancer lesions
V Teixeira and others
Nature Medicine, 2019. Volume 25, issue 3, pages 517-525.
Recruitment start:
Recruitment end:
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Chief Investigator
Professor Chrissie Thirlwell
Supported by
Cancer Research UK
Experimental Cancer Medicine Centre (ECMC)
Royal Free London NHS Foundation Trust
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
